QAI Labs Ltd. is an early-stage company — a Delaware corporation headquartered in Sugar Land, Texas — building NOVA-3, a computer-aided design suite for multi-specific antibodies. Our thesis is simple: the valuable molecules are the hard ones, and the hard ones have to be designed, not screened. This page is the plain-English version of what we're building and why; the Platform and Benchmarks pages carry the technical detail.
None of these are guarantees. They are the reasons we think this company should exist now rather than later.
Single-target antibodies are commoditizing. The molecules pharma now pays for — trispecific T-cell engagers, conditional costimulation, blood-brain-barrier shuttles — are combinatorial. Folding models predict a structure; they don't compose a multi-arm molecule from validated parts. We compose.
Brute-force screening is slow and expensive. Starting from a curated, schema-typed library of validated modules and ranking in silico turns a months-long hunt into a short design loop — our target is sequence to in-vitro PoC in 8–16 weeks.
Diligence teams need to reproduce a result and trust the invention date. Every NOVA-3 candidate ships with an Evidence Bundle — a SHA-256 root anchored to a public timestamp, with the commands to reproduce the claim. That is a procurement feature, not a science-fair trick.
We use quantum hardware where it plausibly helps — active-space corrections on hard glycan chemistry — and report the hardware fraction of every job. We make no claim of demonstrated quantum advantage in ground-state chemistry. The restraint is deliberate.
An honest snapshot. Everything below is live or filed; nothing here is a projection. Forward-looking work is in the timeline further down, marked as planned.
The five-layer NOVA-3 stack, plus a no-login demo anyone can run in the browser — real ESMFold structure prediction and an interactive design Playground.
1,200+ pre-validated VH/VL pairs across 80+ therapeutic targets, plus linkers, hinges, and effectors — each module provenance-stamped and schema-typed.
P1 trispecific TCE (in-silico PoC), P2 BBB shuttle (in-vitro PoC), P3 senolytic bispecific (lead candidate ranked). Provisionals PROV-2026-001/002/003 filed. Wet-lab validation is scheduled, not yet complete.
Cryptographic provenance on every result — a SHA-256 root committed to a public timestamp via OpenTimestamps, with reproduction commands attached. Verifiable from the Predict page.
Shipped milestones are marked done; everything dated forward is planned and labelled as such. We update this list as reality changes it.
If you run pharma BD, a partner lab, or a fund looking at AI-and-biology, we'd like to hear from you. The first conversation usually starts with a program walkthrough and an Evidence Bundle review.
QAI Labs Ltd. · Sugar Land, Texas · partner@qailabs.co